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Introduction: Interferon-g (IFN-g) inducible protein 10kD (IP-10) and IFN-g release assays (IGRAs) are
immunodiagnostic tests aiming to identify the presence of speciﬁc cellular immune responses, inter-
preted as markers for latent infection with Mycobacterium tuberculosis. Incubation at higher tempera-
tures could affect IFN-g and IP-10 responsiveness in order to improve the performance of IP-10 release
assays and IGRAs.
Aim: The aim of this study was to assess the robustness of whole blood based IP-10 release assay and
IGRAs and the effect of hyper-thermic incubation (39 C) on the diagnostic accuracy of IP-10 release assay
and IGRAs.
Results: We included 65 patients with conﬁrmed pulmonary tuberculosis and 160 healthy controls from
6 European centres collaborating in the TBnet. In patients, IP-10 responses increased 1.07 (IQR 0.90e1.36)
fold and IFN-g responses decreased 0.88 (IQR 0.57e1.02) fold, with 39 C compared to 37 C incubation
temperature. At 37 C IGRA sensitivity was 85% and IP-10 sensitivity was 82%, whereas speciﬁcity was
97% for both tests (p > 0.8). These minor changes observed as a result of hyper-thermic incubation were
not sufﬁcient to impact IGRA and IP-10 release assay test performance.
Conclusion: The performance of IGRA and IP-10 release assays is robust despite variations in the incu-
bation temperature between 37 C and 39 C.
© 2015 Elsevier Ltd. All rights reserved.artment of Infectious Disease
00 S., Copenhagen, Denmark.1. Introduction
The World Health Organization's Post 2015 Global Tuberculosis
(TB) strategy, calls for renewed research focus on improving the
T. Blauenfeldt et al. / Tuberculosis 98 (2016) 7e128tools employed for predicting the risk of development of tubercu-
losis in persons at risk [1]. IFN-g release assays (IGRAs) are
immunodiagnostic tests aiming to identify the presence of Myco-
bacterium tuberculosis speciﬁc cellular immune responses. In the
absence of active TB, positive TSTor IGRA responses are interpreted
as markers for latent infection with M. tuberculosis [2e4].
Compared to tuberculin skin test (TST), IGRAs are more speciﬁc in
BCG-vaccinated individuals, however IGRAs performance are
generally not superior to the TST for the prediction of the devel-
opment of TB in persons at risk [5e7]. Children and HIV-infected
individuals with ongoing viral replication have increased risk of
progression to disease, however IGRAs have shown poor perfor-
mance in these groups [8,9]. IGRAs are highly susceptible to vari-
ability by numerous factors at multiple levels, including biological
variability in the tested individual and technical variability from
assay manufacturing, pre-analytical processing, and analytical
testing [2,10]. Several attempts have been made to improve the
performance of the immunodiagnostic tests including stimulation
with antigens associated with mycobacterial dormancy or switch-
ing readout markers [11e13]. IP-10, a chemokine expressed in
concert with IFN-g is a novel biomarker explored alternatively to
the TST and IGRAs for the identiﬁcation of individuals at risk for the
development of TB [14e18]. IP-10 is expressed in 100 fold higher
levels allowing for simpler readout platforms including lateral ﬂow
and potentially also improved detection of infection in young
children and HIV-infected individuals [14e17].
In a recent proof-of-concept study we investigated another
means of improving IGRA performance, incubation of samples at
hyperthermic temperature (39 C) [19]. Fever is an essential
component of normal immune function in-vivo and the immuno-
modulatory effects of fever and febrile-range temperatures have
been well categorized and include effects on cytokine expression,
antigen presentation, and lymphocyte proliferation [20e24]. In a
whole blood model we showed that IFN-g and IP-10 release was
signiﬁcantly increased at 39 C compared to 37 C incubation
temperature in response to M. tuberculosis speciﬁc antigens and to
mitogens in patients with TB. In a similar experiment in healthy
controls, we demonstrated increased IP-10 release in response to
Bacillus Calmette-Guerin (BCG) vaccine recall antigens, but failed to
show an effect on IFN-g release in the same samples. The effects of
hyper-thermic incubation were much more pronounced in TB pa-
tients and suggested that this simple approach could improve the
diagnostic tests for infection with M. tuberculosis.
The aim of this study was to assess the robustness of IGRA and
IP-10 release assays and potential effects of hyper-thermic incu-
bation on IP-10 and IFN-g release and diagnostic potential in a
cohort of patients with conﬁrmed TB and healthy controls.
2. Material and methods
2.1. Patient material
Following ethical board approval and informed consent TB pa-
tients and healthy controls were enrolled at the University Hospital
of Copenhagen, Denmark, the University Hospital of Freiburg,
Germany, the Medical Clinic of the Research Center Borstel, Ger-
many, the Tuberculosis Centre of Vila Nova de Gaia, Portugal, the
Cantonal Hospital of St.Gallen, Switzerland and the Hospital
German Trias i Pujol, Badalona, Spain, where investigators are
collaborating in the TBnet (www.tb-net.org). We prospectively
included patients with culture and or NAAT conﬁrmed active TB
who were >18 years of age and up to 1 month into TB treatment.
Cases were included irrespective of HIV status and other immuno-
suppressive conditions. Controls with no ethnic, travel or other
exposure, and no prior TB treatment or diagnosis were includedamong medical students and lab personnel. Demographics, HIV
status, ethnic, travel and exposure history was noted for all patients
and controls.
2.2. Samples
Whole blood was stimulated in the QuantiFERON®Gold in-tube
(Qiagen, Venlo, The Netherlands; QFT) vacutainers. The QFT test
comprises one vacutainer tube coated with M. tuberculosis speciﬁc
peptides, one positive control tube coated with phytohemagglu-
tinin and one uncoated negative control tube. Each participant had
2 sets of QFT-IT tests done. One was incubated at 37 C for 20 h, the
other for 20 h at 39 C. Samples were handled in parallel
throughout. Following incubation, plasma supernatants from both
sets were analysed per protocol with the QFT ELISA (Qiagen, Venlo,
The Netherlands) and with an in-house IP-10 ELISA using pre-set
cut-off for positive test [25]. Each participating centre had a dedi-
cated incubator set at 39 C with regular temperature checks
throughout the study period.
2.3. Ethical
Inclusion of study participants was approved by the Ethical
Committee of the Municipality of Copenhagen, Denmark (KF-01-
278477) and subsequently in all participating centers.
2.4. Statistics
IP-10 and IFN-g concentrations were compared with non-
parametric paired tests. Test results were classiﬁed according to
pre-set (QFT; Qiagen, NL [26]), or published (IP-10 [25]) algorithms.
Test results were compared with McNemars test, a p-value of
p < 0.05 was considered signiﬁcant. Calculations and data man-
agement was done using SAS 9.2 (SAS institute, Cary, NC, USA) and
GraphPadPrism 5.0 (GraphPad Software, Inc, La Jolla, CA, USA).
3. Results
3.1. Patient material
We included 65 patients with conﬁrmed pulmonary TB by M.
tuberculosis culture and 160 healthy unmatched controls from 6
European centres (Table 1). The controls were from Germany
(n¼ 53), Spain (n¼ 9) and Denmark (n¼ 98) and the patients were
fromGermany (n¼ 37), Switzerland (n¼ 13) and Portugal (n¼ 15).
The IP-10 and IFN-g results from the 98 Danish controls have pre-
viously been presented in another unrelated study [18]. Patients
were predominantly male (44/65 (68%) vs. 58/160 (36%)), signiﬁ-
cantly older than the controls (41 (inter quartile range (IQR) 29e52)
vs. 25 years (IQR 24e34), and 23/65 (35%) of patients compared to
11/160 (7%) of controls were born outside Western Europe
(p < 0.001).
3.2. Biomarker responses: 39 C vs. 37 C
In patients, IP-10 responses to antigen stimulation were signif-
icantly increased with 39 C compared to 37 C incubation tem-
perature (median 1.07 fold (IQR 0.90e1.36), p ¼ 0.004). In contrast,
IFN-g responses were signiﬁcantly reduced (median 0.88 fold (IQR
0.57e1.02), p ¼ 0.002) (Figure 1). In controls, the effects of hyper-
thermic incubation were minimal for both markers, although
there was a discrete but signiﬁcant decrease in the IFN-g response
(Figure 2). IP-10 responsiveness to mitogen stimulation with in-
cubation at 39 Cwas 1.11 fold increased (IQR 0.89e1.44, p < 0.001),
and not signiﬁcantly different between cases and controls
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shot the range of the QFT ELISA (10 IU/ml), the impact of hyper-
thermia could not be accurately assessed.
3.3. ROC curve analysis
We compared the ROC curves of the 4 test modalities and found
comparable AUCs 0.95e0.98 (Figure 4).
3.4. Test results, concordance and changes in positivity rates: 39 C
vs. 37 C
At 37 CQFTsensitivitywas 56/65 (85%) and IP-10 sensitivitywas
53/65 (82%), whereas speciﬁcity was 155/160 (97%) for both tests.
Increasing the incubation temperature to 39 C rendered compa-
rable results: 52/65 (80%) sensitivity for QFT and 53/65 (82%) for IP-
10, respectively; and speciﬁcity 156/158 (99%) for QFT and 153/157
(97%) for IP-10, respectively (p > 0.57 for all comparisons, Table 2).
At 37 C results from 3 patients (4%) were concordant negative;
results from 5 (8%) were IP-10 positive and QFT negative, and re-
sults from 7 (11%) were QFT positive and IP-10 negative/indeter-
minate. In the controls, results from 154 (96%) were concordant
negative, 4 results were concordant positive (3%) and 1 (1%) was IP-
10 positive, QFT negative. At 39 C results from 3 QFT and 1 IP-10
positive patients converted to negative, respectively (p > 0.80
compared to 37 C).
4. Discussion
We assessed whether variations in temperature between 37 C
and 39 C inﬂuence the performance of whole blood based IGRA
and IP-10 release assays for the diagnosis of infection with M.
tuberculosis. Under normal incubation temperature of 37 C, IP-10
release assays and IGRAs performed similar across the 6 sites, and
in agreement with previous publications [11,25,27]. Incubation at
39 C increased IP-10 release and decreased IFN-g release in
response to M. tuberculosis-antigens and mitogen stimulation in
patients with conﬁrmed TB. However, these differences did not
inﬂuence test performance, as there was no signiﬁcant difference in
positive, negative and indeterminate results associated withTable 1
Baseline.
Patients Controls
n (%) 65 160
Sex 44 (68) 58 (36)
Age (IQR) 41 (29e52) 25 (24e34)
Country of birth
West Europe 32 (50) 151 (94)
Africa 6 (9) 0 (0)
Asia 8 (13) 3 (2)
East Europe/Russia 16 (25) 1 (1)
Americas 1 (2) 4 (2)
Unknown 1 (2) 1 (1)
HIV þ 3 (5) 0 (0)
e 49 (75) 0 (0)
unknown 13 (20) 160 (100)
Immunsuppressed Yes 5 (8) 0 (0)
No 60 (92) 160 (100)
Prior TB diagnosis Yes 10 (15) 0 (0)
No 55 (85) 160 (100)
Unknown 0 (0) 0 (0)
Exposure to a TB patient Yes 13 (20) 10 (6)
No 25 (38) 150 (94)
Unknown 27 (42) 0 (0)
Stay in high endemic
area >2 months
Yes 22 (34) 6 (4)
No 28 (43) 153 (95)
Unknown 15 (23) 1 (1)incubation temperature. The ﬁndings are in contrast to the litera-
ture [22,23] and our previous proof-of-concept study [19]. One
study explored the impact of hypothermic (35 C) incubation on
QFT performance and found little impact [28], suggesting that the
QFT performs consistently over a wide range of incubation tem-
peratures (35C-39 C).
The current study was designed to validate the ﬁndings of that
small study comparing 8 TB patients and 7 controls [19]. The initial
study had two parts: A BCG-vaccine recall study in healthy controls,
and a TB diagnostic study comparing TB patients and healthy con-
trols. The TB diagnostic part demonstrated higher levels of IFN-g
and IP-10 responses (4.1 and 3.5 fold, respectively) to M. tubercu-
losis antigens after incubation at 39 C versus 37 C in patients with
conﬁrmed TB and no change in controls; whereas the BCG-vaccine
recall study showed a smaller, but signiﬁcant 1.3 fold increase in IP-
10 release and no effect on IFN-g responses. The data shown here
were comparable to our previous results from the BCG-vaccine
recall model, but not the TB model. We did not see differences in
the responses between the four centres contributing samples from
TB patients, wherefore a technical bias seems unlikely in this study.
The initial study was small and the risk of type 1 error is high, but
we have no other obvious technical explanation for the differences
between the two studies.
The concept that hyperthermia facilitates immune responses is
well documented and it is established that fever-range tempera-
ture 39C-40 C is most favourable [20e24]. Detailed in-
vestigations in the mouse model as well as human studies have
explored these effects of in vitro and whole body thermal stress
showing increased adhesion of naïve T cells and lymphocyte
extravasation of lymphoid organs [29], enhanced T cell prolifera-
tion and differentiation of naïve to effector T cells [30,31], and
enhanced responsiveness of both macrophages [32] and T cells
[22,23,31]. The effects are inducible with prolonged (days) and
short (hours) thermal stress and maintained for at least 24 h
[22,31e33]. The underlying mechanisms are incompletely under-
stood, however the effects appear to affect T cells and antigen
presenting cells independently [32,34] possibly through direct ef-
fects on the membrane ﬂuidity [22] and induction of heat-shock
proteins [35e37].
Studies exploring the effect of hyperthermia on cytokine release
in cell mediated immune response assays, demonstrate augmented
IFN-g, IL-2, IL-1 and TNF-a release upon challenge with peptides,
PPD, and mitogens [22,31,33,34]. Except for one study using 2 h
in vitro pre-incubation of whole blood at 39 C before PBMC puri-
ﬁcation [22], no studies have explored the effects of hyperthermic
incubation in a whole blood assay as done herein. It is tempting to
speculate that our unexpected negative ﬁndings could at least in
part be explained by the presence of erythrocytes during incuba-
tion. One of the effects of hyperthermic incubation is increased
eryptosis (the suicidal death of erythrocytes) [38]. Eryptosis is
triggered by thermal activation of Ca2þ permeable cation channels
and Ca2þ inﬂux, leading to cell shrinkage and scrambling of the cell
membrane with phosphatidylserine exposure at the cell surface
[38,39]. Eryptosis is further potentiated by ongoing inﬂammation
as well as direct actions of rifampicin [40,41], suggesting a negative
synergy inﬂuencing our ﬁndings in the TB patient group. Phos-
phatidylserine is a potent and directly acting inhibitor of T cell
effector functions, effects which could be further debilitated by the
drop in extracellular Ca2þ [42,43]. A selective negative effect on T
cell responses in the presence of hyperthermically augmented
monocyte responsiveness [32] could explain the otherwise contra-
intuitive ﬁnding of increased IP-10 responses in spite of lower IFN-g
release. However, this clinical study was not designed to explore
these complex interactions. Further studies are needed exploring
the interplay of eryptosis and cell mediated immunity.
Figure 1. Results of antigen speciﬁc IP-10 and IFN-g release assays incubated at 39 C and 37 C from 65 patients with TB. Upper panel: each dot indicates an individual patient
response, solid line at median; dotted line presents the cut off for positive test (established for incubation at 37 C). Lower panel present differences in antigen dependent IP-10 and
IFN-g response at 39 C compared to 37 C; responses are arranged from lowest to highest. Dotted lines indicate the inﬂection point i.e. where differences change from negative to
positive.
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In conclusion, we assessed the impact of hyperthermic incuba-
tion on the magnitude of IFN-g and IP-10 release in response toFigure 2. Results of antigen speciﬁc IP-10 and IFN-g release assays incubated at 39 C and
response, solid line at median; dotted line presents the cut off for positive test (established fo
IFN-g response at 39 C compared to 37 C; responses are arranged from lowest to highest.
positive.ESAT-6, CFP10 and TB7.7p4 peptide stimulation in a whole blood
cell mediated immune response assay. Twenty hour incubation at
39 C compared to 37 C augmented themagnitude of IP-10 release,
but had a negative effect on IFN-g release. The observe changes37 C from 160 healthy controls. Upper panel: each dot indicates an individual patient
r incubation at 37 C). Lower panel present differences in antigen dependent IP-10 and
Dotted lines indicate the inﬂection point i.e. where differences change from negative to
Figure 3. Results of mitogen speciﬁc IP-10 release assays incubated at 39 C and 37 C
in 225 individuals (160 healthy controls and 65 TB patients). Upper panel: each dot
indicates an individual response, solid line at median. Lower panel: Differences in
mitogen dependent IP-10 response at 39 C compared to 37 C are arranged from
lowest to highest. Dotted lines indicate the inﬂection point i.e. where differences
change from negative to positive.
Table 2
IP-10 release assay and QFT test results from 65 TB patients and 160 controls
incubated at 37 C and 39 C. n (%); Pos. denotes positive; neg. denotes negative;
indet. denotes indeterminate.
37 C 39 C
IP-10 QFT IP-10 QFT
TB Pos. 53 (82) 56 (85) 52 (80) 53 (82)
Neg. 11 (17) 8 (12) 11 (17) 11 (17)
Indet. 1 (2) 1 (2) 2 (3) 1 (2)
Total 65 65 65 65
Control Pos. 5 (3) 4 (3) 4 (3) 2 (1)
Neg. 155 (97) 155 (97) 153 (96) 156 (98)
Indet. 0 (0) 1 (1) 3 (1) 2 (1)
Total 160 160 160 160
T. Blauenfeldt et al. / Tuberculosis 98 (2016) 7e12 11were not sufﬁcient to impact IGRA and IP-10 release assay test
performance, suggesting that the whole blood tests are robust and
tolerate variation in the incubation temperature between 37 C
and 39 C.Figure 4. ROC curve analysis. Cut off independent comparison of the diagnostic po-
tential of IP-10 and IFN-g release in response to antigen stimulation in QFT tubes.Conﬂicts of interest
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